American Association for Clinical Chemistry

Day Zero Diagnostics Welcomes Molecular Diagnostics Experts to its Advisory Board

Retrieved on: 
Wednesday, August 24, 2022
Zero, Hive, Massachusetts General Hospital, Machine learning, Subclinical infection, American Association for Clinical Chemistry, MassChallenge, Research, CEO, Gene, Eastern Virginia Medical School, Infection, Microbiology, Death, Associate, R, WGS, Culture, Molecular epidemiology, University, LinkedIn, Department, Diagnosis, Senior, Coronavirus Scientific Advisory Board (Turkey), Lancet, Hospital, CLIA, Harvard University, Molecular design software, Whole genome sequencing, Medical microbiology, Advisory board, DZD, Drug resistance, Twitter, LLC, Sepsis, Association, Review, Patient, Vaccine, Antibiotics, Medicine, Pathology

BOSTON, Aug. 24, 2022 /PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced the addition of Dr. Amy Mathers and Rob Crisp to the company's Advisory Board.

Key Points: 
  • DZD is poised to revolutionize infectious disease diagnosis, reducing time to diagnosis of infections from days to hours
    "We are pleased to welcome Dr. Amy Mathers and Rob Crisp to the Day Zero Diagnostics Advisory Board.
  • "I'm impressed with Day Zero Diagnostics' sequencing-based rapid diagnostic technology that shortens the traditional wait time of a culture.
  • Crisp is currently Vice President, Research and Development at Molecular Designs, a team of doctors and scientists working to advance molecular diagnostics.
  • Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital.

Taiwan Excellence Pavilion Showcasing at The AACC Expo (American Association for Clinical Chemistry) for the First Time

Retrieved on: 
Wednesday, August 10, 2022
Health Technology, Health, Medical Supplies, Medical Devices, AACC, CYP, FAD, Multimedia, Association, American Association, The, American Association for Clinical Chemistry, ATE, NAT, TECO, Chroma ATE, Autumn, First Time, IDRC, Medicine, TAITRA

Taiwan Excellence is leading a team of award-winning medical testing products to attend the largest and most influential global expo, AACC in Chicago, aiming for post-pandemic business opportunities.

Key Points: 
  • Taiwan Excellence is leading a team of award-winning medical testing products to attend the largest and most influential global expo, AACC in Chicago, aiming for post-pandemic business opportunities.
  • View the full release here: https://www.businesswire.com/news/home/20220804006111/en/
    Taiwan Excellence Pavilion Showcasing at The AACC Expo (American Association for Clinical Chemistry) for the First Time (Photo: Business Wire)
    Many countries have been reopening gates to travelers around the world during this post-pandemic era.
  • The maiden show from Taiwan Excellence Pavilion without a doubt has attracted undivided attention from the rest of the world.
  • As Taiwan Excellence Award-Winning products are showcased at AACC, it shows that the testing industry from Taiwan is growing firm and strong.

Biological Dynamics to Present at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit

Retrieved on: 
Wednesday, August 3, 2022
Technology, Research, Medical Devices, Nanotechnology, Biotechnology, Health, General Health, Science, Oncology, Organic acid, CFO, UBS, AACC, Genomics, American Association for Clinical Chemistry, Nanoparticle, Association, Biomarker, American Association, Biology, Blood, Cancer, Machine learning, Twitter, CEO, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Disruptive innovation, Audience, Pharmaceutical industry

Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at their earliest stages, today announced that the company will participate at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

Key Points: 
  • Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at their earliest stages, today announced that the company will participate at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.
  • Dr. Paul Billings, CEO and Kevin Han, CFO are scheduled to participate in a fireside chat with UBS analysts on Wednesday, August 10th at 1:00 p.m.
  • To join the live webcast, visit Biological Dynamics website: https://biologicaldynamics.com/company-events .
  • Biological Dynamics, Inc. is a biotechnology company committed to improving global health outcomes by detecting diseases at their earliest stages.

Menarini Silicon Biosystems and DIESSE announced strategic partnership to distribute CHORUS TRIO in North America

Retrieved on: 
Tuesday, July 26, 2022
Silicon, Association, Erythrocyte sedimentation rate, ESR, CEO, Partnership, Solution, Marketing, American Association, American Association for Clinical Chemistry, Multimedia, Biotechnology, AACC, Patient, Efficiency, Diesse, Pharmaceutical industry, Medical device, Fine chemical

CHICAGO, July 26, 2022 /PRNewswire/ -- Menarini Silicon Biosystems Inc, a US company part of the Menarini Group and DIESSE Diagnostica Senese Società Benefit S.p.A., a company with over 40 years of experience in the world of laboratory diagnostics, announced today at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.

Key Points: 
  • "I am glad that Menarini Silicon Biosystems Inc. will distribute CHORUS in the USA" announced Massimiliano Boggetti CEO of DIESSE.
  • With the broadest range of immunometric mono-test panels, CHORUS TRIO also features technological innovation and Italian design" he added.
  • DIESSE CHORUS line is a great choice to make testing easy, immediate and accurate when lab automation is not an option.
  • Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinicians and clinical researchers with access to unparalleled data on rare cells and their molecular characterization.

Menarini Silicon Biosystems and DIESSE announced strategic partnership to distribute CHORUS TRIO in North America

Retrieved on: 
Tuesday, July 26, 2022
Silicon, Association, Erythrocyte sedimentation rate, ESR, CEO, Partnership, Solution, Marketing, American Association, American Association for Clinical Chemistry, Biotechnology, AACC, Patient, Efficiency, Diesse, Pharmaceutical industry, Medical device, Fine chemical

CHICAGO, July 26, 2022 /PRNewswire/ -- Menarini Silicon Biosystems Inc, a US company part of the Menarini Group and DIESSE Diagnostica Senese Società Benefit S.p.A., a company with over 40 years of experience in the world of laboratory diagnostics, announced today at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.

Key Points: 
  • "I am glad that Menarini Silicon Biosystems Inc. will distribute CHORUS in the USA" announced Massimiliano Boggetti CEO of DIESSE.
  • With the broadest range of immunometric mono-test panels, CHORUS TRIO also features technological innovation and Italian design" he added.
  • DIESSE CHORUS line is a great choice to make testing easy, immediate and accurate when lab automation is not an option.
  • Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinicians and clinical researchers with access to unparalleled data on rare cells and their molecular characterization.

Advanced Instruments Introduces the OsmoPRO® MAX Automated Osmometer to Maximize Clinical Lab Productivity

Retrieved on: 
Tuesday, July 26, 2022
Data management, Association, CEO, MAX, Efficiency, Osmometer, Compliance, American Association for Clinical Chemistry, Automation, American Association, Medical device

NORWOOD, Mass., July 26, 2022 /PRNewswire/ -- Advanced Instruments announced today at the American Association for Clinical Chemistry trade show in Chicago the newest addition to its clinical line of freezing point osmometers, the OsmoPRO MAX Automated Osmometer.

Key Points: 
  • NORWOOD, Mass., July 26, 2022 /PRNewswire/ -- Advanced Instruments announced today at the American Association for Clinical Chemistry trade show in Chicago the newest addition to its clinical line of freezing point osmometers, the OsmoPRO MAX Automated Osmometer .
  • As the leading authority in osmometry, Advanced Instruments designed the OsmoPROMAX for clinical laboratories of all sizes seeking higher productivity through automation.
  • The OsmoPRO MAX, like all of the osmometers in Advanced Instruments' portfolio, uses the industry-preferred freezing point depression method to provide reliable results in minutes.
  • "The OsmoPRO MAX delivers the ease of use, automation, and data management features today's clinical laboratories seek," said Byron Selman, CEO of Advanced Instruments.

Advanced Instruments Introduces the OsmoPRO® MAX Automated Osmometer to Maximize Clinical Lab Productivity

Retrieved on: 
Tuesday, July 26, 2022
Data management, Association, CEO, MAX, Efficiency, Osmometer, Compliance, American Association for Clinical Chemistry, Automation, American Association, Medical device

NORWOOD, Mass., July 26, 2022 /PRNewswire/ -- Advanced Instruments announced today at the American Association for Clinical Chemistry trade show in Chicago the newest addition to its clinical line of freezing point osmometers, the OsmoPRO MAX Automated Osmometer.

Key Points: 
  • NORWOOD, Mass., July 26, 2022 /PRNewswire/ -- Advanced Instruments announced today at the American Association for Clinical Chemistry trade show in Chicago the newest addition to its clinical line of freezing point osmometers, the OsmoPRO MAX Automated Osmometer .
  • As the leading authority in osmometry, Advanced Instruments designed the OsmoPROMAX for clinical laboratories of all sizes seeking higher productivity through automation.
  • The OsmoPRO MAX, like all of the osmometers in Advanced Instruments' portfolio, uses the industry-preferred freezing point depression method to provide reliable results in minutes.
  • "The OsmoPRO MAX delivers the ease of use, automation, and data management features today's clinical laboratories seek," said Byron Selman, CEO of Advanced Instruments.

Microbix Presenting STI Multiplex Test Controls at AACC

Retrieved on: 
Tuesday, July 26, 2022
Goal, TSX, Association, Diagnosis, STI, Vertically transmitted infection, GLOBE, Genital ulcer, Treponema pallidum, U.S. FDA, QAP, Laboratory, TGA, ISO 9001, Herpes simplex virus, Health, American Association, Health Canada, Ulcer, QAP (Colombia), News, Organization, CE, American Association for Clinical Chemistry, GUD, AACC, Company, FDA, Poster, Engineering, Antigen, Medical device, OTCQX, Vaccine, Treponema

GUDs are a current and growing global health concern, with over 20 million new cases each year.

Key Points: 
  • GUDs are a current and growing global health concern, with over 20 million new cases each year.
  • Microbix has overcome challenges in formulation and appears to be the first to develop a multiplex whole-workflow control for GUD assays.
  • Microbix creates proprietary biological products for human health, with over 100 skilled employees and sales approaching C$ 2.0 million per month.
  • Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Clear Labs to Lead Session on Whole Genome Sequencing at AACC Annual Scientific Meeting in Chicago

Retrieved on: 
Monday, July 25, 2022
Clear Labs, DNA, Association, NGS, Eyeish, Infection, Health care, Genomics, CT, Whole genome sequencing, Doctor of Philosophy, Hospital, SAN, Poster, American Association for Clinical Chemistry, American Association, WGS, Hospital-acquired infection, HAI, Automation, Technology, Virulence, AACC, Robotics, Subclinical infection, Antibiotics

SAN CARLOS, Calif., July 25, 2022 /PRNewswire-PRWeb/ -- This week, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is attending and presenting at the The American Association for Clinical Chemistry (AACC) Annual Scientific Meeting + Clinical Lab Expo. The AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Its annual event showcases cutting-edge research, technology and automation shaping the future of diagnostics.

Key Points: 
  • The AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare.
  • Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex workflows for clinical and applied markets.
  • By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs liberates genomics to deliver increased clarity.
  • With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow's novel pathogens.

Cytovale Reveals 10-Minute, 510(k) Pending Cytovale System and IntelliSep Test for Sepsis at AACC 2022

Retrieved on: 
Monday, July 25, 2022
Medical Supplies, Medical Devices, Health, Infectious Diseases, Hospitals, Clinical Trials, Biomedical Advanced Research and Development Authority, Association, United States Department of Health and Human Services, Infection, Diagnosis, PLOS, Mount Everest, Texas Tech University Health Sciences Center, ISI, Physician, Twitter, Critical care, ED, Sepsis, Risk, American Association, American Association for Clinical Chemistry, EDS, Disease, Motion, Multimedia, Triage, Assistant, Machine learning, Decision-making, Emergency department, AACC, Office of the Assistant Secretary for Preparedness and Response, Patient, LinkedIn, NPV, ICU, Department, Red blood cell, PPA, Emergency, Medical device

The IntelliSep test was recently named an AACC Disruptive Technology Award Semifinalist and is also being featured in the Disruptive Tech area of the exhibit hall during the meeting.

Key Points: 
  • The IntelliSep test was recently named an AACC Disruptive Technology Award Semifinalist and is also being featured in the Disruptive Tech area of the exhibit hall during the meeting.
  • Were excited to share the IntelliSep test with the global laboratory science community at AACC 2022.
  • Cytovales investigational IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patients risk of sepsis.
  • Assessment of a cellular host response test as a sepsis diagnostic for those with suspected infection in the Emergency Department.